Skip to Content

Popular

Having trouble identifying your medications? Try the Pill Identifier

Quickly identify pills, tablets and capsules using the web's most comprehensive Pill Identification Wizard.

Get Started

Featured Tool

Worried about drug interactions? Use the Interactions Checker

The drug interactions tool allows you to check for drug-drug and drug-food interactions.

Check Now

Featured Tool

Discover treatment options with the Symptom Checker

This interactive decision guide helps identify the underlying cause of common symptoms.

Get Started

Featured Tool

Custom search for Medical Transcriptionists?

Use our custom wildcard and phonetic search to assist in identifying drugs where the exact spelling is unknown and only the pronunciation is available.

Get Started

Drug Information

Tools

News & Alerts

Professionals

Top 100 Drugs

More A-K · More L-Z · By Class · UK Medicines
For Consumers For Professionals For Researchers Announcements
Latest FDA New Drug Approvals

More

Drugs in Development (Not yet approved)

More

Drugs.com is the most popular, comprehensive and up-to-date source of drug information online. Providing free, peer-reviewed, accurate and independent data on more than 24,000 prescription drugs, over-the-counter medicines & natural products.

Posted today in New Drug Approvals

FDA Approves Luxturna (voretigene neparvovec-rzyl) Gene Therapy to Treat Patients with a Rare Form of Inherited Vision Loss

The U.S. Food and Drug Administration today approved Luxturna (voretigene neparvovec-rzyl), a new gene therapy, to treat children and adult patients with an inherited form of vision loss that may result in blindness. Luxturna is the first directly administered gene therapy approved in the U.S. that targets a disease caused by mutations in a specific...

Posted today in Clinical Trials

Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of Avapritinib (BLU-285) in Patients with Advanced Systemic Mastocytosis Showing Evidence of Strong Clinical Activity

Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced new data from its ongoing Phase 1 clinical trial of avapritinib (formerly known as BLU-285), a potent and highly selective KIT and PDGFRα inhibitor in development for patients...

Featured Topic Centers

Posted today in Medical

FDA Approves Gene Therapy, Luxturna (Voretigene Neparvovec-rzyl) for Rare Form of Blindness

A new gene therapy to treat children and adults with a rare type of inherited vision loss has been approved by the U.S. Food and Drug Administration. It's the first gene therapy approved in the United States for a disease caused by mutations in a specific gene, and only the third gene therapy ever approved. People with this disorder "now have a chance...

Posted 2 days ago in New Drug Approvals

Aclaris Therapeutics Receives FDA Approval for Eskata (hydrogen peroxide) Topical Solution, 40% (w/w) for the Treatment of Raised Seborrheic Keratoses

Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Eskata (hydrogen peroxide) topical solution, 40% (w/w) for the treatment of raised seborrheic keratoses, or SKs. SKs are non-cancerous skin growths that affect more than 83 million American...

Posted today in Medical

Heroin Vaccine Blunts Drug's Effect in Animals

An experimental heroin vaccine has shown promise in an early animal study. In mice and rats, the vaccine triggered antibodies that prevented heroin from crossing the blood-brain barrier. "By eliciting antibodies that bind with heroin in the blood, the vaccine aims to block the euphoria and addictive effects [in the brain]," explained researcher Gary...

Posted today in Medical

Cancer Survivors Often Face Another Hurdle: Faster Aging

Treatments that help people beat cancer also can cause them to age prematurely and die sooner, Mayo Clinic researchers report. Cancer survivors naturally age faster than others who haven't had cancer, and are more likely to develop long-term health problems related to aging while they're still relatively young, the study authors said. These ailments...

Posted today in Medical

Gene Therapy, Luxturna (Voretigene Neparvovec-rzyl), Approved for Rare Inherited Vision-Loss Disorders

Luxturna, a form of gene therapy, has been approved to treat a rare group of inherited vision disorders that can lead to blindness. The disorders are broadly grouped together and known as biallelic RPE65 mutation-associated retinal dystrophy. They affect a combined 1,000 to 2,000 people in the United States, the U.S. Food and Drug Administration said...

Posted today in Medical

U.S. Lifts Ban on Laboratory-Made Lethal Viruses

U.S. officials said on Tuesday they've lifted a moratorium enacted three years ago on funding lab experiments that would create lethal viruses. This type of research can now occur if a scientific panel finds the potential benefits outweigh any risks, said Dr. Francis Collins, head of the U.S. National Institutes of Health. The research in question...

Posted today in New Drug Approvals

Aerie Pharmaceuticals Announces U.S. FDA Approval of Rhopressa (netarsudil ophthalmic solution) 0.02% for Patients with Open-Angle Glaucoma or Ocular Hypertension

(BUSINESS WIRE)--Dec. 18, 2017-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced that the U.S. Food and Drug...

Posted 2 days ago in Medical

Tougher State Laws Curb Vaccine Refusers

A Washington state law aimed at discouraging nonmedical childhood vaccine exemptions seems to have worked, a new study finds. The legislation, enacted in 2011, required parents to talk to a doctor before they could get their child exempted from vaccinations for nonmedical reasons. Researchers found that after the law went into effect, the state's...

Read more news...

Recently added consumer and prescribing information: Ozempic, Juluca, Hemlibra, Prevymis, Fasenra, Calquence, Yescarta, Verzenio, Trelegy Ellipta, Solosec

Posted in Blog

Drugs.com Receives eHealthcare Leadership Silver Award

We are proud to announce that Drugs.com has been awarded a Silver Award for “Best Consumer General Health Site” in the 2017 eHealthcare Leadership Awards. Jane Weber Brubaker, chair of the eHealthcare Leadership Awards, notes that “Winners range from small and large healthcare provider organizations, to business-to-business and medical device companies, but they share these […]

Posted in Blog

Drugs.com Recognized as ‘Health Information Website Brand of the Year’ in 2017 Harris Poll EquiTrend® Study

The team at Drugs.com is humbled and heartened to have been recognized as the ‘Health Information Website Brand of the Year‘ in the 2017 Harris Poll EquiTrend Study. The annual Harris Poll EquiTrend® Study measures and compares a brand’s health over time and against key competitors. Other categories measured include travel, financial, automotive and entertainment. […]

Posted in Blog

REMS@FDA: An Upgraded Patient Safety Program

REMS Overview Fact: Prescription drugs are complicated, and they are getting more complicated every day. Issues with complex drugs and side effects is not just a concern for the healthcare provider, it directly impacts the patient and caregiver, too. We’ve all heard the long list of adverse effects and warnings that unfold during a primetime […]

See more blog posts or follow us on twitter.

Drugs.com Mobile Apps

The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Available for Android and iOS devices.

Explore Apps